Trade secrets: an alternative for life sciences IP?

Over the past decade, three high-profile US Supreme Court decisions—known by their shorthand names as Alice, Mayo, and Myriad—have generated significant uncertainty over what is and isn’t patentable.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

In-house counsel

LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?

4 November 2026 AI agents are no longer just helping patent lawyers with their workload. Some are now doing the work themselves. In-house counsel from Insitro, Illumina, 10x Genomics and Invenra discuss how much can be handed over and whether humans could be replaced.

Careers

Dykema’s new trademark pro will be a ‘tremendous asset’ to clients

4 November 2026 Joining in Wisconsin, the senior counsel brings “sophisticated” trademark experience and leadership, and counts biotechnology among her sectors.

In-house counsel

In-house counsel rethink patent filing strategies as costs mount

3 November 2026 With budgets under pressure, counsel from Pfizer, ALX Oncology and BioMarin share how they are reassessing portfolios, trimming costs and prioritising key markets at LSPN Fall.

More features

Latham lands pharma and tech expert in London

HeartFlow targets AI cardiac imaging rival over patents and trade secrets

‘Companies that don’t leverage AI will struggle to keep up’: Umicore IP chief

Haynes Boone expands in California with new office

Brazilian firm appoints patent strategist to lead department

Scientist and Chinese biotech targeted by Beam in secrets suit

Clifford Chance recruits new head of Asia-Pac

New UK High Court judge named as replacement for Justice Meade

Trade secrets: an alternative for life sciences IP?

More on this story

Editor's picks

Editor's picks

More features